Filing Details

Accession Number:
0001104659-24-034671
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-14 20:52:35
Reporting Period:
2024-03-13
Accepted Time:
2024-03-14 20:52:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1781983 Aprea Therapeutics Inc. APRE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1187572 Iii B John Henneman 3805 Old Easton Road
Doylestown PA 18902
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-13 6,860 $7.29 8,139 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Tranche A Warrant Acquisiton 2024-03-13 3,430 $0.00 3,430 $0.00
Common Stock Tranche B Warrant Acquisiton 2024-03-13 3,430 $0.00 3,430 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,430 2024-03-13 No 4 P Direct
3,430 2024-03-13 No 4 P Direct
Footnotes
  1. The exercise price of the Tranche A Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share.
  2. Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
  3. The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.
  4. The exercise price of the Tranche B Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share.
  5. Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
  6. The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.